trial

Cognitive Behavioral Therapy for Sleep and Circadian Disturbances (CBT-I) in Treatment-Resistant Schizophrenia

NCTId NCT06749444
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Recruiting
Enrollment 60 (estimated)
Sponsored by Jimmi Nielsen
Primary completion 2026-06-30
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Recruiting
Enrollment
60 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2024-11-28
Primary completion
2026-06-30
Eligibility
ALL · 18 Years · 64 Years

Interventions & indications

Drugs
CBT-ICBT

Sponsors

Jimmi NielsenLead Sponsor

Investigators

1
Jimmi Nielsen, PhDStudy Director

Sites

1 total
Glostrup, Denmark, Denmark

Facts & assertions

4 sourced
Enrollment
60
Phase
NA
Primary Completion Date
2026-06-30
Status
RECRUITING
relationships
The graph out of here
drug
CBT-I
drug
CBT
drug
lead_sponsor
Jimmi Nielsen
company
indication
Sleep Initiation and Maintenance Disorders
indication
Schizophrenia, Treatment-Resistant
indication
Treatment-refractory Schizophrenia
indication
investigator
Jimmi Nielsen, PhD
person